AL
ALLO.US Allogene Therapeutics Inc
- Market cap
- USD 291M
- P/E
- -
- P/B
- 0.73x
- ROE
- -46.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ALLO.US undervalued?
Graham numberThe Graham number of Allogene Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Allogene Therapeutics Inc fundamental analysis
No fundamental analysis for Allogene Therapeutics Inc yet.
Allogene Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engine…
Full company profileAllogene Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Allogene Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 38.3M | 38.5M | 243K | 95.0K | 22.0K | 0.00 | 6.19M |
| Gross Profit | 0.00 | -1.50M | -5.03M | -11.5M | 38.5M | 243K | 95.0K | 22.0K | -12.4M | - |
| Operating Income | -2.00K | -193M | -202M | -258M | -256M | -335M | -328M | -273M | -207M | -197M |
| EBITDA | 22.0K | -207M | -180M | -251M | -245M | -321M | -313M | -243M | -177M | -169M |
| Net Income | -2.00K | -212M | -185M | -233M | -245M | -330M | -327M | -258M | -191M | -181M |
| EPS | 0.00 | -2.36 | -1.83 | -1.94 | -1.80 | -2.30 | -2.09 | -1.32 | -0.87 | -0.52 |
| Balance Sheet | ||||||||||
| Total Assets | 0.00 | 774M | 718M | 1.23B | 1.05B | 822M | 643M | 549M | 416M | 511M |
| Total Liabilities | 2.00K | 70.7M | 88.8M | 148M | 126M | 155M | 131M | 127M | 123M | 119M |
| Shareholders' Equity | -2.00K | 703M | 629M | 1.08B | 925M | 667M | 512M | 422M | 293M | 393M |
| Cash & Short-term Investments | 0.00 | 721M | 531M | 828M | 457M | 517M | 449M | 292M | 250M | 293M |
| Total Debt | - | 34.5M | 53.0M | 53.8M | 73.1M | 101M | 95.1M | 90.8M | 83.3M | 68.0M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -44.7M | -44.7M | -137M | -115M | -185M | -221M | -238M | -200M | -149M | -108M |
| Capital Expenditure | 5.33M | 3.23M | 50.8M | 66.0M | 21.4M | 5.19M | 1.52M | 694K | 386K | 245K |
| Free Cash Flow | - | -47.9M | -188M | -181M | -206M | -226M | -239M | -201M | -150M | -108M |
| Ratios | ||||||||||
| ROE | - | -30.1% | -29.3% | -21.6% | -26.5% | -49.5% | -63.9% | -61.0% | -65.3% | -46.1% |
| ROA | - | -27.3% | -25.7% | -19.0% | -23.3% | -40.1% | -50.9% | -46.9% | -45.9% | -35.4% |
| Net Profit Margin | - | - | - | -608.9% | -636.1% | -135,726.3% | -344,489.5% | -1,170,863.6% | - | -2,923.6% |
| Debt to Equity | - | 0.05x | 0.08x | 0.05x | 0.08x | 0.15x | 0.19x | 0.21x | 0.28x | 0.17x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Allogene Therapeutics Inc dividends
Allogene Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Allogene Therapeutics Inc
- Insiders 10.99%
- Institutions 84.66%
- Public & others 4.35%
- Shares outstanding 346M
- Free float 283M
Top funds holding ALLO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Select Biotechnology | 10.0M | 2.91% | -2.92% | Aug 2026 |
| State Street® SPDR® S&P® Biotech ETF | 9.93M | 2.88% | +2.69% | Oct 2026 |
| Vanguard Capital Opportunity Inv | 9.41M | 2.72% | +0.25% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 8.67M | 2.51% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 6.76M | 1.96% | 0.00% | Oct 2026 |
| PRIMECAP Odyssey Aggressive Growth | 3.48M | 1.01% | 0.00% | Sep 2026 |
| abrdn Life Sciences Investors | 3.31M | 0.96% | +12.62% | Sep 2026 |
| Belfius Equities Cure C Cap | 3.00M | 0.87% | 0.00% | Apr 2026 |
| Fidelity Small Cap Index | 2.99M | 0.86% | +2.67% | Aug 2026 |
| iShares Russell 2000 Value ETF | 2.48M | 0.72% | 0.00% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 2.17M | 0.63% | +0.27% | Oct 2026 |
| abrdn Healthcare Investors | 1.95M | 0.56% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 1.86M | 0.54% | -0.19% | Oct 2026 |
| Columbia Small Cap Value Discv A | 1.82M | 0.53% | +0.73% | Sep 2026 |
| BlackRock Advantage Small Cap Core Instl | 1.76M | 0.51% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 1.54M | 0.45% | +1.11% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 1.43M | 0.41% | +0.24% | Oct 2026 |
| Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 1.31M | 0.38% | +0.08% | Oct 2026 |
| BGF World Healthscience A2 | 1.28M | 0.37% | -33.41% | Jul 2026 |
| iShares U.S. Small-Cap Eq Fac ETF | 1.23M | 0.36% | 0.00% | Oct 2026 |
Top institutions holding ALLO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 30.1M | 8.73% | +57.91% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 22.4M | 6.50% | +491.22% | Jun 2026 |
| Pfizer Inc | 22.0M | 6.38% | 0.00% | Jun 2026 |
| State Street Corp | 19.0M | 5.51% | +119.69% | Jun 2026 |
| TPG GP A, LLC | 18.7M | 5.42% | 0.00% | Jun 2026 |
| Sio Capital Management, LLC | 13.3M | 3.86% | 0.00% | Jun 2026 |
| PRIMECAP Management Company | 13.1M | 3.80% | +56.61% | Jun 2026 |
| Vanguard Capital Management, LLC | 12.2M | 3.52% | +75.78% | Jun 2026 |
| FMR Inc | 12.0M | 3.48% | +655.37% | Jun 2026 |
| Citadel Advisors Llc | 10.1M | 2.92% | +48.49% | Jun 2026 |
| Two Sigma Investments LLC | 7.78M | 2.25% | +44.81% | Jun 2026 |
| Geode Capital Management, LLC | 7.05M | 2.04% | +70.93% | Jun 2026 |
| The Goldman Sachs Group Inc | 6.15M | 1.78% | +122.29% | Jun 2026 |
| GordonMD Global Investments LP | 5.30M | 1.53% | +270.49% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 5.10M | 1.47% | +47.78% | Jun 2026 |
| Patient Square Capital LP | 5.05M | 1.46% | +46.38% | Jun 2026 |
| Aberdeen Group PLC | 5.00M | 1.45% | +242.07% | Jun 2026 |
| Millennium Management LLC | 4.84M | 1.40% | +45.81% | Jun 2026 |
| D. E. Shaw & Co LP | 4.71M | 1.36% | +70.45% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 4.64M | 1.34% | -13.78% | Jun 2026 |
Allogene Therapeutics Inc company profile
- Company name
- Allogene Therapeutics Inc
- Ticker
- ALLO.US
- Exchange
- USA Stocks
- Listed since
- Oct 11, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 150
- Fiscal year end
- December
- Address
- 210 East Grand Avenue, South San Francisco, CA, United States, 94080
- Phone
- 650 457 2700
- Website
- allogene.com
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Allogene Therapeutics Inc management
9- Dr. Arie S. Belldegrun F.A.C.S., M.D.Co-Founder & Executive Chairman · born 1949
- Dr. Zachary J. Roberts M.D., Ph.D.President, CEO & Director · born 1978
- Mr. Joshua A. KazamCo-Founder & Director · born 1977
- Dr. David D. Chang M.D., Ph.D.Co-Founder & Director · born 1960
- Ms. Annie YoshiyamaSenior VP of Finance, Corporate Controller & Principal Accounting Officer · born 1984
- Mr. Benjamin M. BeneskiSenior VP & Chief Technical Officer · born 1977
- Mr. Earl M. Douglas Esq.Senior VP, General Counsel, Compliance Officer & Corporate Secretary · born 1963
- Ms. Susan R. LundeenChief People Officer · born 1966
- Ms. Christine CassianoExecutive VP, Chief Corporate Affairs & Brand Strategy Officer